\n<\/p>\n
HONG KONG SAR – EQS PINUP \u00ae (commonly known According to IMS HONG KONG SAR – EQS Newswire – 16 December 2020 –\u00a0 A fully integrated biopharmaceutical company — Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK) is pleased to announce that PINUP\u00ae (Voriconazole Tablets) has been successfully approved by the National Medical Products Administration (“NMPA”) for Bioequivalence (“BE”) certification …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/10224"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=10224"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/10224\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=10224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=10224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=10224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nNewswire – 16 December 2020 –\u00a0 A fully integrated biopharmaceutical
\ncompany — Uni-Bio Science Group
\nLimited<\/a> (the “Company”, together with its subsidiaries, the “Group”; Stock
\ncode: 00690.HK) is pleased to announce that PINUP\u00ae (Voriconazole Tablets) has
\nbeen successfully approved by the National Medical Products Administration
\n(“NMPA”) for Bioequivalence (“BE”) certification with the acceptance number of H20055751
\n(50mg). In order to meet the national requirements for improving the quality of
\ngeneric drugs, the Group launched the quality advancement and therapeutic
\neffect BE experiment in 2018. In August 2019, the Group had completed all the
\nBE experiments, and had submitted the results to the NMPA. The approval will facilitate
\nits hospital tenders and listings, especially in national procurement, to achieve
\na larger market share in anti-fungal infection drug market. This approval is
\nvery timely, Voriconazole has been included in the announcement for national
\nprocurement in 8th<\/sup> December 2020, and the Group’s PINUP \u00ae will be
\neligible to participate. Even though there are three manufactures that has
\npassed quality consistency evaluation for this product, there are only two
\nmanufactures that has passed BE certification for the 50mg formulation, the
\nGroup being one of them. Therefore, the Group is in a great position to quickly
\nexpand its market share, supplying high quality Voriconazole without big
\ndiscounts in pricing.<\/p>\n
\nas Voriconazole tablets) is a major drug for the treatment of severe fungal
\ninfections. As the first line treatment recommended by clinical guidelines,
\nVoriconazole takes action by blocking the growth of the fungal cell wall, and
\nis widely used in oncology, hematology, respiratory, and ICUs patients who have
\ncompromised immune systems.<\/p>\n
\nstatistics, the market size for China’s anti-fungal medicine in 2017 amounted
\nto RMB4.9 billion, of which Voriconazole accounted for the biggest share of
\napproximately 50%. The market value for anti-fungal medicines between 2014 and 2017
\nmaintained a double-digit growth, a level that surpassed the growth of the
\nChinese pharmaceutical market of 4%-9%. According to PDB and Menet, the percentage
\nof the orally-administered Voriconazole in all Voriconazole formulation is 37% in
\n2019 compared with 35% in 2017, representing an increasing trend in oral form
\nmarket. In recent years and foreseeable future, there is a continuing shift in
\ntreatment paradigm towards oral Voriconazole due to its use as maintenance
\ntherapy, as well as the convenient oral formulation against injection
\nformulation.\u00a0 <\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"